# Index

## A

<table>
<thead>
<tr>
<th>Term</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>AA</td>
<td>See Autoaugmentation (AA)</td>
</tr>
<tr>
<td>Abdominal leak point pressures (ALPPs)</td>
<td>13</td>
</tr>
<tr>
<td>Abdominal pressure, urethral meatus</td>
<td>36</td>
</tr>
<tr>
<td>defined</td>
<td>13</td>
</tr>
<tr>
<td>UDS</td>
<td>81</td>
</tr>
<tr>
<td>AD</td>
<td>See Autonomic dysreflexia (AD)</td>
</tr>
<tr>
<td>American Urological Association (AUA)</td>
<td>56</td>
</tr>
<tr>
<td>antibiotic prophylaxis, urodynamic studies</td>
<td>6</td>
</tr>
<tr>
<td>score</td>
<td>56</td>
</tr>
<tr>
<td>Amyotrophic lateral sclerosis (ALS)</td>
<td>80</td>
</tr>
<tr>
<td>Artificial urinary sphincter (AUS)</td>
<td>44</td>
</tr>
<tr>
<td>AdvanV™ transobturator sling</td>
<td>46</td>
</tr>
<tr>
<td>bladder outlet obstruction</td>
<td>51</td>
</tr>
<tr>
<td>description</td>
<td>44</td>
</tr>
<tr>
<td>postprostatectomy stress incontinence</td>
<td>45</td>
</tr>
<tr>
<td>surgical options</td>
<td>44</td>
</tr>
<tr>
<td>videourodynamics</td>
<td>48</td>
</tr>
<tr>
<td>Augmentation cystoplasty (AC). See also Lower urinary tract dysfunction (LUTD)</td>
<td></td>
</tr>
<tr>
<td>AA/ureterocystoplasty</td>
<td>102</td>
</tr>
<tr>
<td>bladder augmentation</td>
<td>101</td>
</tr>
<tr>
<td>BoNT-A</td>
<td>103</td>
</tr>
<tr>
<td>CIC</td>
<td>102</td>
</tr>
<tr>
<td>concomitant procedures</td>
<td>102</td>
</tr>
<tr>
<td>contracted tuberculous/bladder extrophy</td>
<td>102</td>
</tr>
<tr>
<td>early complications</td>
<td>103</td>
</tr>
<tr>
<td>high-capacity, low-pressure reservoir</td>
<td>101</td>
</tr>
<tr>
<td>IC/BPS</td>
<td>102</td>
</tr>
<tr>
<td>indications</td>
<td>102</td>
</tr>
<tr>
<td>long-term complications</td>
<td>103</td>
</tr>
<tr>
<td>median bladder capacity</td>
<td>102</td>
</tr>
<tr>
<td>reservoir perforation</td>
<td>103</td>
</tr>
<tr>
<td>urodynamic studies</td>
<td>103–106</td>
</tr>
<tr>
<td>urologist’s role</td>
<td>101</td>
</tr>
<tr>
<td>AUS</td>
<td>See Artificial urethral sphincter (AUS)</td>
</tr>
<tr>
<td>Autoaugmentation (AA)</td>
<td>102</td>
</tr>
<tr>
<td>Autonomic dysreflexia (AD)</td>
<td>28</td>
</tr>
<tr>
<td>bladder distension</td>
<td>82</td>
</tr>
<tr>
<td>constipation</td>
<td>80</td>
</tr>
<tr>
<td>defined</td>
<td>28</td>
</tr>
<tr>
<td>hyperplastic nodules</td>
<td>55</td>
</tr>
<tr>
<td>lab work</td>
<td>57, 59, 60</td>
</tr>
<tr>
<td>medical therapy</td>
<td>56</td>
</tr>
<tr>
<td>office-based surgical procedures</td>
<td>56</td>
</tr>
<tr>
<td>physical examination</td>
<td>57, 58, 60</td>
</tr>
<tr>
<td>PSA testing</td>
<td>56</td>
</tr>
<tr>
<td>risk factors</td>
<td>55</td>
</tr>
<tr>
<td>treatment</td>
<td>58, 60, 62</td>
</tr>
<tr>
<td>UDS</td>
<td>57–62</td>
</tr>
<tr>
<td>Benign prostatic obstruction</td>
<td>18</td>
</tr>
<tr>
<td>Bladder diverticula</td>
<td></td>
</tr>
<tr>
<td>congenital and acquired</td>
<td>127</td>
</tr>
<tr>
<td>cystometrogram and pressure flow</td>
<td>128, 129</td>
</tr>
<tr>
<td>detrusor trabeculation with bilateral</td>
<td>29</td>
</tr>
<tr>
<td>diverticulum development</td>
<td>127</td>
</tr>
<tr>
<td>lab work</td>
<td>128</td>
</tr>
<tr>
<td>physical examination</td>
<td>127–128</td>
</tr>
<tr>
<td>and renal deterioration</td>
<td>55</td>
</tr>
<tr>
<td>treatment</td>
<td>129</td>
</tr>
<tr>
<td>Bladder hypersensitivity</td>
<td>22–24</td>
</tr>
<tr>
<td>Bladder infections</td>
<td>89–90</td>
</tr>
<tr>
<td>Bladder neck obstruction. See Primary bladder neck obstruction (PNBO)</td>
<td></td>
</tr>
<tr>
<td>Bladder outlet obstruction (BOO). See also Benign prostatic hyperplasia (BPH)</td>
<td></td>
</tr>
<tr>
<td>cystoceles obstruction</td>
<td>70–72</td>
</tr>
<tr>
<td>demographic and urodynamic factors</td>
<td>94</td>
</tr>
<tr>
<td>diagnosis</td>
<td></td>
</tr>
<tr>
<td>anatomic obstruction</td>
<td>65–66</td>
</tr>
<tr>
<td>functional obstruction</td>
<td>66</td>
</tr>
<tr>
<td>external sphincter, dysfunctional voiding</td>
<td>72–73</td>
</tr>
<tr>
<td>history and physical examination</td>
<td>66</td>
</tr>
<tr>
<td>iatrogenic bladder infections</td>
<td>89–90</td>
</tr>
<tr>
<td>stress urinary incontinence</td>
<td>90–91</td>
</tr>
<tr>
<td>lower urinary tract conditions</td>
<td>94</td>
</tr>
<tr>
<td>primary bladder neck obstruction</td>
<td>67–69</td>
</tr>
<tr>
<td>sling obstruction</td>
<td>70</td>
</tr>
<tr>
<td>symptoms in females</td>
<td>65</td>
</tr>
<tr>
<td>tracings</td>
<td>73–78</td>
</tr>
<tr>
<td>urodynamics, role</td>
<td>66–67</td>
</tr>
<tr>
<td>voiding dysfunction</td>
<td>94</td>
</tr>
<tr>
<td>Botulinum neurotoxin A (BoNT-A) injections</td>
<td>101, 103</td>
</tr>
<tr>
<td>BPH. See Benign prostatic hyperplasia (BPH)</td>
<td></td>
</tr>
</tbody>
</table>

## B

<table>
<thead>
<tr>
<th>Term</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baden-Walker Grade 1 cystocele</td>
<td>69</td>
</tr>
<tr>
<td>Benign prostatic hyperplasia (BPH)</td>
<td></td>
</tr>
<tr>
<td>aging male population</td>
<td>55</td>
</tr>
<tr>
<td>AUA symptom score</td>
<td>56</td>
</tr>
<tr>
<td>benign prostatic enlargement</td>
<td>55</td>
</tr>
<tr>
<td>characteristic LUTS</td>
<td>55</td>
</tr>
<tr>
<td>DO</td>
<td>56</td>
</tr>
<tr>
<td>hyperplastic nodules</td>
<td>55</td>
</tr>
<tr>
<td>lab work</td>
<td>57, 59, 60</td>
</tr>
<tr>
<td>medical therapy</td>
<td>56</td>
</tr>
<tr>
<td>office-based surgical procedures</td>
<td>56</td>
</tr>
<tr>
<td>physical examination</td>
<td>57, 58, 60</td>
</tr>
<tr>
<td>PSA testing</td>
<td>56</td>
</tr>
<tr>
<td>risk factors</td>
<td>55</td>
</tr>
<tr>
<td>treatment</td>
<td>58, 60, 62</td>
</tr>
<tr>
<td>UDS</td>
<td>57–62</td>
</tr>
<tr>
<td>Benign prostatic obstruction</td>
<td>18</td>
</tr>
<tr>
<td>Bladder diverticula</td>
<td></td>
</tr>
<tr>
<td>congenital and acquired</td>
<td>127</td>
</tr>
<tr>
<td>cystometrogram and pressure flow</td>
<td>128, 129</td>
</tr>
<tr>
<td>detrusor trabeculation with bilateral</td>
<td>29</td>
</tr>
<tr>
<td>diverticulum development</td>
<td>127</td>
</tr>
<tr>
<td>lab work</td>
<td>128</td>
</tr>
<tr>
<td>physical examination</td>
<td>127–128</td>
</tr>
<tr>
<td>and renal deterioration</td>
<td>55</td>
</tr>
<tr>
<td>treatment</td>
<td>129</td>
</tr>
<tr>
<td>Bladder hypersensitivity</td>
<td>22–24</td>
</tr>
<tr>
<td>Bladder infections</td>
<td>89–90</td>
</tr>
<tr>
<td>Bladder neck obstruction. See Primary bladder neck obstruction (PNBO)</td>
<td></td>
</tr>
<tr>
<td>Bladder outlet obstruction (BOO). See also Benign prostatic hyperplasia (BPH)</td>
<td></td>
</tr>
<tr>
<td>cystoceles obstruction</td>
<td>70–72</td>
</tr>
<tr>
<td>demographic and urodynamic factors</td>
<td>94</td>
</tr>
<tr>
<td>diagnosis</td>
<td></td>
</tr>
<tr>
<td>anatomic obstruction</td>
<td>65–66</td>
</tr>
<tr>
<td>functional obstruction</td>
<td>66</td>
</tr>
<tr>
<td>external sphincter, dysfunctional voiding</td>
<td>72–73</td>
</tr>
<tr>
<td>history and physical examination</td>
<td>66</td>
</tr>
<tr>
<td>iatrogenic bladder infections</td>
<td>89–90</td>
</tr>
<tr>
<td>stress urinary incontinence</td>
<td>90–91</td>
</tr>
<tr>
<td>lower urinary tract conditions</td>
<td>94</td>
</tr>
<tr>
<td>primary bladder neck obstruction</td>
<td>67–69</td>
</tr>
<tr>
<td>sling obstruction</td>
<td>70</td>
</tr>
<tr>
<td>symptoms in females</td>
<td>65</td>
</tr>
<tr>
<td>tracings</td>
<td>73–78</td>
</tr>
<tr>
<td>urodynamics, role</td>
<td>66–67</td>
</tr>
<tr>
<td>voiding dysfunction</td>
<td>94</td>
</tr>
<tr>
<td>Botulinum neurotoxin A (BoNT-A) injections</td>
<td>101, 103</td>
</tr>
<tr>
<td>BPH. See Benign prostatic hyperplasia (BPH)</td>
<td></td>
</tr>
</tbody>
</table>

## C

<table>
<thead>
<tr>
<th>Term</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cerebrovascular accident (CVA)</td>
<td>80</td>
</tr>
<tr>
<td>Classic neurogenic bladder</td>
<td></td>
</tr>
<tr>
<td>lab work</td>
<td>111, 112</td>
</tr>
<tr>
<td>physical examination</td>
<td>111</td>
</tr>
</tbody>
</table>
Classic neurogenic bladder (cont.)
small-capacity, overactive bladder, 110
symptoms, 110
tethered cord, 110
treatment, 111
Clean intermittent catheterization (CIC)
AA, 101
artificial urinary sphincter, 115
bladder emptying, 102
high-grade reflux, female gender and initiation, 110
intradetrusor injection, onabotulinumtoxinA, 30
mucus production, 103
myelomeningocele, 117
surgical intervention, 58
voiding diary, 104
CMG. See Cystometrogram (CMG)
Complex UDS systems
electrodes, 2–4
exam table, 4
fluid media, 2
fluoroscopy, 4
intra-abdominal catheters, 2
intravesical catheters, 2
printing data vs. transmission to EMR, 4
purchase and maintenance, 4–5
software, 4
uroflow meter, 4
wireless systems, 4
Congenital neurogenic bladder, 123
Cough leak point pressure, 13
CVA. See Cerebrovascular accident (CVA)
Cystocele obstruction, 70–72
Cystometric capacity
filling rate of bladder, 13, 58–60
UDS, 13
voiding diary, 12
Cystometrogram (CMG), 1, 28, 91, 95, 96, 98
Cystoscopy
bladder wall trabeculation, 50
“Christmas tree” appearance, 118
evaluation, 126, 130
normal urethra without strictures, 57
obstruction/erosion/PBNO, 66
Detrusor contractility, 15, 44, 58, 62, 99
Detrusor external sphincter dyssynergia (DESD), 66, 67
bladder trabeculation and diverticula, 30
and dysfunctional voiding, 16, 17
increased EMG activity, 29
Detrusor leak point pressure (DLPP) defined, 11
upper tract deterioration, 11, 101
Detrusor overactivity (DO), 83, 86
abdominal pressure, 35
anticholinergics, 69
bladder outlet obstruction with, 25
compliance, 11
cystocele, 71, 72
detrusor trabeculation with bilateral bladder, 29, 30
Fowler’s syndrome, 73
radiology licenses, 4
safety requirements, 4
sling obstruction, 70
structural anomalies, 28
video-urodynamics, 2, 49
Fowler’s syndrome
dysfunctional voiding, 72–73
Electrodes, complex UDS systems, 2–4
Electromyography (EMG), 2, 3, 6, 16, 28, 29, 32, 45, 50, 66, 68, 72, 86
Electronic medical record (EMR), 4
ethernet capability, 5
printing data vs. transmission, 4
Female SUI
in abdominal pressure, 35
complicated, 35, 36
cystometry, 37–38
de novo urinary storage symptoms, 39
diagnosis of, 35
DO, 35
long-standing history, 39–41
LPP, 36–37
LUTS, 35
mixed urinary incontinence, 35
synthetic midurethral slings, 38–39
UPP, 37
urodynamics and surgical treatment, 35
Filling cystometry, 10, 37
Fluid media, complex UDS systems, 2
Fluoroscopy
anatomy, urinary tract, 9
bladder neck and external sphincter function, 66
complex UDS systems, 4
cystocele, 71, 72
detrusor trabeculation with bilateral bladder, 29, 30
Fowler’s syndrome, 73
radiology licenses, 4
safety requirements, 4
sling obstruction, 70
structural anomalies, 28
video-urodynamics, 2, 49
Fowler’s syndrome
dysfunctional voiding, 72–73
external sphincter relaxation, 66
history, 72–73
lab work/studies, 72
physical examination, 72
treatment options, 72–73
UDS, 72

G
Genitourinary fistula
cystoscopic evaluation and upper tract imaging, 130
lab work, 130
physical examination, 130
treatment, 130–131
UDS, 130, 131
vesicovaginal and urethrovaginal fistula, 130

H
Hinman-Allen syndrome, 66
Hypertension, 30–31, 45, 94, 116
Hypocontractility, 56, 79, 82
Hypothyroidism, 30–31, 85–87
Hypotonic/tonic bladder
lab work, 113–115
physical examination, 113
treatment, 115–116

I
Iatrogenic BOO
bladder infections, 89–90
SUI, 90–91
Incontinence quality of life questionnaire (I-QoL), 44
International consultation on incontinence questionnaire short form
(ICIQ-SF), 44
International Continence Society (ICS), 2, 6, 21, 44, 78
InterStim® device, 29
Intra-abdominal pressure
mixed urinary incontinence, 35
rectal catheter placement, 83, 86
SUI, 43
Intravesical pressure, 2, 3, 7, 13, 29, 37, 45
Intrinsic sphincteric deficiency (ISD)
defined, 36
incontinence improvement, 38
MUICP values, 37
patients with ALPP/VLPP, 37
slings placement with leakage, 36
urethral hypermobility, 36
Involuntary detrusor contractions
associated urinary incontinence, 84
CMG, 28
DO, 12
I-QoL. See Incontinence quality of life questionnaire (I-QoL)

L
Leak point pressures (LPPs)
abdominal force evaluation, 36
defined, 37
leakage, radiographic visualization, 37
patient positioning, 37
urinary leakage, 37

Lower urinary tract dysfunction (LUTD)
augmentation cystoplasty, 101, 102
bladder symptoms, 101
characteristics, 101
clinical signs, 101
neurogenic, 104
pathophysiology, 101, 102
urologist’s role, 101
Lower urinary tract symptoms (LUTS)
AUA, 56
POP, 93
UDS with prolapse reduction, 94
urinary urgency and diurnal urinary frequency, 45

M
Magnetic resonance imaging (MRI), 29, 83–85, 125, 126
Male SUI
24-h pad test, 44
AUS, 44
bulbourethral slings, 45
congenital and acquired neurogenic disorders, 43
cystourethroscopy, 44
Kegel exercises and penile clamp, 47, 48
LUTS, 45, 46
minimally invasive and nerve sparing approaches, 43
nonoperative interventions, 44
normal bladder cycling, 44
periurethral bulking agents, 45
postprostatectomy incontinence, 43
PVP, 50–52
quality of life information, 44
radical prostatectomy, 43
UDS, 44
urological practice and patient’s quality of life, 43
Mixed urinary incontinence
filling cystometry, 37–38
intra-abdominal pressure, 35
patient’s incontinence, 38
urodynamic evaluation, 36
VALUE trial, 38
Multichannel VUDS, 81, 83, 86
Multiple sclerosis (MS)
clinical patterns, 80
detrusor-external sphincter dyssynergia, 66
history, 83
lab work/studies, 83
neurogenic causes, obstruction, 66
physical examination, 83
treatment options, 83–85
UDS, 83
voiding dysfunction, neurogenic, 79–80
Myelomeningocele (MM), 80, 109–111, 113, 115, 116

N
Neurogenic bladder
CIC and anticholinergic medication, 110
classic (see Classic neurogenic bladder)
clinical evaluation, 110
description, 109
after fetal myelomeningocele repair, 109
micturition, 110
neuroanatomical pathways, 109
obstruction
hypothyroidism, 85–87
Neurogenic bladder (cont.)
  multiple sclerosis, 83–85
  quadriplegia, 80–83
  prenatal myelomeningocele repair, 109
  therapies, 109
  transplant evaluation, 116, 118–123
  urodynamic testing, 109
Neurogenic OAB
  hypertension and hypothyroidism, 30–32
  SCI, 29–31
Neurogenic voiding dysfunction, 79, 80

O
  Obstructive voiding, 55, 79, 89, 90, 94, 101, 110
  Occult stress urinary incontinence, 15, 22, 39, 94
  Overactive bladder (OAB)
    bladder hypersensitivity, 23–24
    bladder outlet obstruction, 24–26
    DO, 22
    neurogenic (see Neurogenic OAB)

P
  Parkinson’s disease (PD)
    neurogenic OAB, 27
    urinary retention, 58
    urodynamic tracing, 31, 57
Pelvic organ prolapse (POP)
  BOO (see Bladder outlet obstruction (BOO))
  labwork, 95, 97
  middle-aged women, 93
  physical examination, 94–95, 97
  and SUI
    anti-incontinence procedure, 93
    CARE, 93
    concomitant colposuspension, 93
    MUS, 94
    urodynamic stress incontinence, 93
    treatment, 96, 98
  UDS, 95–98
Pelvic Organ Prolapse Quantification (POP-Q) system, 21, 95, 97
Percutaneous tibial nerve stimulation (PTNS), 22, 29
POP. See Pelvic organ prolapse (POP)
Post void residual (PVR), 17, 18, 21, 27, 44, 69, 109, 111, 116
Pressure flow studies (PFS), 28, 29
Pressure-flow urodynamic (PFUD) study, 9, 10
Primary bladder neck obstruction (PNBO), 19, 66–69, 75
Primary-progressive pattern, 80
Progressive-relapsing pattern, 80
PTNS. See Percutaneous tibial nerve stimulation (PTNS)
PVR. See Post void residual (PVR)

Q
  Quadriplegia, 80–83

R
  Relapsing-remitting pattern, 80
  Renal transplantation, 102, 110, 123

S
  Sacral neuromodulation (SNM), 29
  Secondary progressive pattern, 80
  Self- intermittent catheterization (SIC), 88
  Sensory urgency, 28
  Simple UDS systems, 1–2
  Skene’s duct cyst, 66
  Sling obstruction, 69, 70, 89–91
  Society of Urodynamics, Female Pelvic Medicine, and Urogenital Reconstruction (SUFU), 27
Spinal cord injury (SCI), 27–31, 80, 85
Stress urinary incontinence (SUI)
  female (see Female SUI)
  history, 90
  male (see Male SUI)
  physical examination, 90–91
  treatment options, 91
  UDS, 91 (see also Urodynamics)
  Stress-induced detrusor overactivity, 14, 35, 37–38
SUFU. See Society of Urodynamics, Female Pelvic Medicine, and Urogenital Reconstruction (SUFU)

T
  Three-way stopcock approach, 6, 7
  Transurethral resection of prostate (TURP), 44, 51, 58

U
  UPP. See Urethral pressure profile (UPP)
  Urethral diverticula, 66
    cystoscopic evaluation, 125
    physical examination, 125–126
    symptoms, 125
    treatment, 127
    typical repair, 125
    UDS, 126–127
  Urethral hypermobility, 36
  Urethral pressure profile (UPP), 2, 4, 37
  Urgency urinary incontinence (UUI), 22, 27, 28, 30, 94
  Urgent PC® device, 29
  Urinary incontinence, stress, 90–91
  Urinary tract infection (UTI)
    gross hematuria, 85
    mucus production, 103
    nocturnal enuresis, 116
  Urinary urgency, 21, 22, 32, 35, 38, 45, 47, 83, 89, 125, 127
  Urodynamics (UDS)
    anticholinergic, 39
    ASC, 93
    benefits, 1
    bladder outlet, 36
    clinical obstruction, 17–19
    closure pressures, 36
    coarse sensation, 10–11
    complex UDS systems, 2–5
    compliance, 11–12
    concomitant anti-incontinence surgery, 94
    continence, 13–15
    contributory factors, 36
    contractility, 15–16
    contractions (detrusor overactivity), 12–14
    coordination, 16–17
    coarse sensation, 10–11
    cystometry, 12–13, 37
    detrusor function, 39
    diagnostic tool, 36
    incontinence, 9, 12, 14, 15
    ISD, 36
    LPPs (see Leak point pressures (LPPs))
midurethral sling, 18
mixed urinary incontinence, 38
multichannel, 3
occult stress incontinence, 94
POP and LUTS, 93
repetitive pelvic stress, 36
setup, 5–6
simple UDS systems, 1–2
synthetic midurethral slings, 38
troubleshooting, 6–7
UPP, 37
urethral hypermobility, 36
Urodynamics tracing, 90, 91
Uroflow meter, complex UDS systems, 4
UTI. See Urinary tract infection (UTI)
UUI. See Urgency urinary incontinence (UUI)

V
Valsalva leak point pressure (VLPP), 13, 37, 38, 44, 94
Vesicoureteral reflux (VUR), 80–83, 86–88
Videourodynamic (VUDS), 48, 49, 81, 83, 86, 87, 103, 111, 113, 116, 122, 129
Voiding cystourethrogram (VCUG), 11, 87, 120

W
Wireless systems, complex UDS systems, 4

Z
Zero pressure, 6